The association between melatonin and episodic migraine: A pilot network meta‐analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy

摘要: Although exogenous melatonin supplementation has been suggested to be effective for episodic migraine prophylaxis, there is no conclusive evidence comparing the efficacy of other FDA-approved pharmacotherapy prophylaxis. The aim current network meta-analysis (NMA) was compare in patients with migraine. randomized placebo-controlled trials or controlled (RCTs) incorporating a placebo study designs were included our analyses. All NMA procedures conducted under frequentist model. primary outcome changes frequency days and response rate after prophylaxis pharmacological interventions. We 25 RCTs total 4499 (mean age = 36.0 years, mean female proportion = 78.9%). demonstrated that oral 3 mg/d (immediate-release) at bedtime associated greatest improvement [mean difference = -1.71 days, 95% confidence interval (CI): -3.27 -0.14 days compared placebo] second highest (odds ratio = 4.19, CI = 1.46 12.00 placebo). Furthermore, 3 mg most preferred intervention among all investigated interventions when improvements frequency, rate, dropout rates any adverse events taken into account. This pilot suggests potential prophylactic role